CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity

Seminars in Immunopathology

Volumn 36, Issue 6, 2014, Pages 627-640

  Corrales Aguilar, Eugenia ^a   Hoffmann, Katja ^b   Hengel, Hartmut ^b  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ADCC; Cytomegalovirus; Fc Rs; IgG; Immune evasion

Indexed keywords

BINDING PROTEIN; FC RECEPTOR IIA; FCGAMMA RECEPTOR I; FCGAMMA RECEPTOR IIB; FCGAMMA RECEPTOR IIC; FCGAMMA RECEPTOR IIIA; FCGAMMA RECEPTOR IIIB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; NEONATAL FC RECEPTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; FC RECEPTOR; LIGAND; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; BINDING AFFINITY; CYTOMEGALOVIRUS INFECTION; ENDOCYTOSIS; FCGR1A GENE; FCGR2A GENE; FCGR2B GENE; FCGR2C GENE; FCGR3A GENE; FCGR3B GENE; GENETIC CODE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMUNOTHERAPY; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; CHEMISTRY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CARRIER PROTEINS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN G; IMMUNOMODULATION; IMMUNOTHERAPY; LIGANDS; PROTEIN BINDING; RECEPTORS, IGG; VIRAL PROTEINS;

EID: 84921936905     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-014-0448-2     Document Type: Review

References (123)

1. Chee MS, Bankier AT, Beck S et al (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125–69
2. Davison AJ, Dolan A, Akter P et al (2003) The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 84:17–28
3. Murphy E, Yu D, Grimwood J et al (2003) Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 100:14976–81. doi:10.1073/pnas.2136652100
4. Stern-Ginossar N, Gur C, Biton M et al (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9:1065–73. doi:10.1038/ni.1642
5. Goodrum F, Reeves M, Sinclair J et al (2007) Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937–45. doi:10.1182/blood-2007–01–070078
6. Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–38. doi:10.1016/S1473–3099(04)01202–2
7. Ji Y-N, An L, Zhan P, Chen X-H (2012) Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep 39:6537–46. doi:10.1007/s11033–012–1482–6
8. Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E (2012) The impact of CMV infection on survival in older humans. Curr Opin Immunol 24:507–11. doi:10.1016/j.coi.2012.04.002
9. Cobbs CS (2013) Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol 25:682–8. doi:10.1097/CCO.0000000000000005
10. Reddehase MJ, Mutter W, Münch K et al (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–8
11. Polić B, Hengel H, Krmpotić A et al (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047–54
12. Jonjić S, Pavić I, Polić B et al (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713–7
13. Klenovsek K, Weisel F, Schneider A et al (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–9. doi:10.1182/blood-2007–06–095414
14. Hengel H, Brune W, Koszinowski UH (1998) Immune evasion by cytomegalovirus-survival strategies of a highly adapted opportunist. Trends Microbiol 6:190–7
15. Mocarski ES (2004) Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707–717. doi:10.1111/j.1462–5822.2004.00425.x
16. Scalzo A, Corbett A (2007) The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol cell … 46–54. doi: 10.1038/sj.icb.7100013
17. Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2:706–13. doi:10.1038/nri891
18. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–42. doi:10.1146/annurev-immunol-032712–095916
19. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77:195–262
20. Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96:179–204. doi:10.1016/S0065–2776(07)96005–8
21. Pincetic A, Bournazos S, DiLillo DJ et al (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15:707–716. doi:10.1038/ni.2939
22. Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune responses. Immunol Rev 236:265–75. doi:10.1111/j.1600–065×.2010.00910.x
23. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47. doi:10.1038/nri2206
24. Takai T, Ono M, Hikida M et al (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346–9. doi:10.1038/379346a0
25. Bolland S, Ravetch JV (1999) Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 72:149–77
26. Karsten CM, Pandey MK, Figge J et al (2012) Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med 18:1401–6. doi:10.1038/nm.2862
27. Nimmerjahn F, Ravetch JV (2011) FcγRs in health and disease. Curr Top Microbiol Immunol 350:105–25. doi:10.1007/82_2010_86
28. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–90. doi:10.1146/annurev.immunol.19.1.275
29. Lu J, Marjon KD, Mold C et al (2012) Pentraxins and Fc receptors. Immunol Rev 250:230–8. doi:10.1111/j.1600–065×.2012.01162.x
30. Du Clos TW (2013) Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013:379040. doi:10.1155/2013/379040
31. Lu J, Marnell LL, Marjon KD et al (2008) Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 456:989–92. doi:10.1038/nature07468
32. Ernst LK, van de Winkel JG, Chiu IM, Anderson CL (1992) Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem 267:15692–700
33. Warmerdam PA, Nabben NM, van de Graaf SA et al (1993) The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. J Biol Chem 268:7346–9
34. Ory PA, Clark MR, Kwoh EE et al (1989) Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 84:1688–91. doi:10.1172/JCI114350
35. Guilliams M, Bruhns P, Saeys Y et al (2014) The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 14:94–108. doi:10.1038/nri3582
36. Hogarth PM, Pietersz GA (2012) Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 11:311–31. doi:10.1038/nrd2909
37. Bruhns P, Iannascoli B, England P et al (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–25. doi:10.1182/blood-2008–09–179754
38. Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640–9. doi:10.1182/blood-2012–01–380121
39. Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9:457–92. doi:10.1146/annurev.iy.09.040191.002325
40. Pan LY, Mendel DB, Zurlo J, Guyre PM (1990) Regulation of the steady state level of Fc gamma RI mRNA by IFN-gamma and dexamethasone in human monocytes, neutrophils, and U-937 cells. J Immunol 145:267–75
41. Veri M-C, Gorlatov S, Li H et al (2007) Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121:392–404. doi:10.1111/j.1365–2567.2007.02588.x
42. Ehrhardt GRA, Cooper MD (2011) Immunoregulatory roles for fc receptor-like molecules. Curr Top Microbiol Immunol 350:89–104. doi:10.1007/82_2010_88
43. Cassard L, Jönsson F, Arnaud S, Daëron M (2012) Fcγ receptors inhibit mouse and human basophil activation. J Immunol 189:2995–3006. doi:10.4049/jimmunol.1200968
44. Van der Heijden J, Breunis WB, Geissler J et al (2012) Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol 188:1318–24. doi:10.4049/jimmunol.1003945
45. Zhao W, Kepley CL, Morel PA et al (2006) Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol 177:694–701
46. Magnusson SE, Engström M, Jacob U et al (2007) High synovial expression of the inhibitory FcgammaRIIb in rheumatoid arthritis. Arthritis Res Ther 9:R51. doi:10.1186/ar2206
47. Metes D, Manciulea M, Pretrusca D et al (1999) Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cells. Eur J Immunol 29:2842–52. doi:10.1002/(SICI)1521–4141(199909)29:09<2842::AID-IMMU2842>3.0.CO;2–5
48. Meknache N, Jönsson F, Laurent J et al (2009) Human basophils express the glycosylphosphatidylinositol-anchored low-affinity IgG receptor FcgammaRIIIB (CD16B). J Immunol 182:2542–50. doi:10.4049/jimmunol.0801665
49. Flinsenberg TWH, Compeer EB, Koning D et al (2012) Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood 120:5163–72. doi:10.1182/blood-2012–06–434498
50. Tridandapani S, Wardrop R, Baran CP et al (2003) TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J Immunol 170:4572–7
51. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–25. doi:10.1038/nri2155
52. Ghetie V, Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18:592–8
53. Rath T, Kuo TT, Baker K et al (2013) The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 33(Suppl 1):S9–17. doi:10.1007/s10875–012–9768-y
54. Ko S-Y, Pegu A, Rudicell RS et al (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. doi:10.1038/nature13612
55. Woof JM, Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4:89–99. doi:10.1038/nri1266
56. Hulett MD, Osman N, McKenzie IF, Hogarth PM (1991) Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG. J Immunol 147:1863–8
57. Zhang Y, Boesen CC, Radaev S et al (2000) Crystal structure of the extracellular domain of a human Fc gamma RIII. Immunity 13:387–95
58. Sondermann P, Huber R, Jacob U (1999) Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J 18:1095–103. doi:10.1093/emboj/18.5.1095
59. Sondermann P, Huber R, Oosthuizen V, Jacob U (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406:267–73. doi:10.1038/35018508
60. Hamerman JA, Lanier LL (2006) Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006:re1. doi: 10.1126/stke.3202006re1
61. Sulica A, Herberman RB (1996) Cytophilic immunoglobulins revisited via natural killer cells. FASEB J 10:1495–504
62. Lux A, Yu X, Scanlan CN, Nimmerjahn F (2013) Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol 190:4315–23. doi:10.4049/jimmunol.1200501
63. Shields RL, Lai J, Keck R et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733–40. doi:10.1074/jbc.M202069200
64. Niwa R, Natsume A, Uehara A et al (2005) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306:151–60. doi:10.1016/j.jim.2005.08.009
65. Niwa R, Sakurada M, Kobayashi Y et al (2005) Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327–36. doi:10.1158/1078–0432.CCR-04–2263
66. Okazaki A, Shoji-Hosaka E, Nakamura K et al (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336:1239–49. doi:10.1016/j.jmb.2004.01.007
67. Radaev S, Motyka S, Fridman WH et al (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276:16469–77. doi:10.1074/jbc.M100350200
68. Langone JJ (1982) Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol 32:157–252
69. Müller MG, Ing JY, Cheng MK-W et al (2013) Identification of a phage-encoded Ig-binding protein from invasive Neisseria meningitidis. J Immunol 191:3287–96. doi:10.4049/jimmunol.1301153
70. Cortese M, Calò S, D’Aurizio R et al (2012) Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc. PLoS One 7:e50166. doi:10.1371/journal.pone.0050166
71. Atalay R, Zimmermann A, Wagner M et al (2002) Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol 76:8596–608
72. Lilley BN, Ploegh HL, Tirabassi RS (2001) Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J Virol 75:11218–21. doi:10.1128/JVI.75.22.11218–11221.2001
73. Frank I, Friedman HM (1989) A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 63:4479–88
74. Lenac T, Budt M, Arapovic J et al (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203:1843–50. doi:10.1084/jem.20060514
75. Sprague ER, Reinhard H, Cheung EJ et al (2008) The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol 82:3490–9. doi:10.1128/JVI.01476–07
76. Thäle R, Lucin P, Schneider K et al (1994) Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol 68:7757–65
77. Budt M, Reinhard H, Bigl A, Hengel H (2004) Herpesviral Fcgamma receptors: culprits attenuating antiviral IgG? Int Immunopharmacol 4:1135–48. doi:10.1016/j.intimp.2004.05.020
78. Namboodiri AM, Budkowska A, Nietert PJ, Pandey JP (2007) Fc gamma receptor-like hepatitis C virus core protein binds differentially to IgG of discordant Fc (GM) genotypes. Mol Immunol 44:3805–8. doi:10.1016/j.molimm.2007.03.022
79. Mercé-Maldonado E (2011) Identification and functional characterization of a novel HCMV-encoded Fcγ receptor blocking CD16-mediated activation of human natural killer cells. Heinrich-Heine-Universität, Düsseldorf
80. Corrales-Aguilar E, Trilling M, Hunold K et al (2014) Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. PLoS Pathog 10:e1004131. doi:10.1371/journal.ppat.1004131
81. Cha TA, Tom E, Kemble GW et al (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70:78–83
82. Varnum SM, Streblow DN, Monroe ME et al (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78:10960–6. doi:10.1128/JVI.78.20.10960–10966.2004
83. Dargan DJ, Douglas E, Cunningham C et al (2010) Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 91:1535–46. doi:10.1099/vir.0.018994–0
84. Dolan A, Cunningham C, Hector RD et al (2004) Genetic content of wild-type human cytomegalovirus. J Gen Virol 85:1301–12
85. Akter P, Cunningham C, McSharry BP et al (2003) Two novel spliced genes in human cytomegalovirus. J Gen Virol 84:1117–22
86. Stanton RJ, Baluchova K, Dargan DJ et al (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120:3191–208. doi:10.1172/JCI42955
87. Crnković-Mertens I, Messerle M, Milotić I et al (1998) Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 72:1377–82
88. Arapovic J, Lenac T, Antulov R et al (2009) Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus. J Virol 83:8198–207. doi:10.1128/JVI.02549–08
89. Mintern JD, Klemm EJ, Wagner M et al (2006) Viral interference with B7–1 costimulation: a new role for murine cytomegalovirus fc receptor-1. J Immunol 177:8422–31
90. Westmoreland D, Watkins JF (1974) The IgG receptor induced by herpes simplex virus: studies using radioiodinated IgG. J Gen Virol 24:167–78
91. Yasuda J, Milgrom F (1968) Hemadsorption by herpes simplex-infected cell cultures. Int Arch Allergy Appl Immunol 33:151–70
92. Watkins JF (1964) Asorption of sensitized sheep erytrocytes to Hela cells infected with herpes simplex virus. Nature 202:1364–5
93. Dubin G, Socolof E, Frank I, Friedman HM (1991) Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol 65:7046–50
94. Nagashunmugam T, Lubinski J, Wang L et al (1998) In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72:5351–9
95. Sprague ERE, Wang C, Baker D, Bjorkman PJP (2006) Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 4:e148. doi:10.1371/journal.pbio.0040148
96. Wiger D, Michaelsen TE (1985) Binding site and subclass specificity of the herpes simplex virus type 1-induced Fc receptor. Immunology 54:565–72
97. Sondermann P, Oosthuizen V (2002) X-ray crystallographic studies of IgG-Fc gamma receptor interactions. Biochem Soc Trans 30:481–486
98. Kutza AS, Muhl E, Hackstein H et al (1998) High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 26:1076–82
99. Ross SA, Arora N, Novak Z et al (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386–9. doi:10.1086/649903
100. Hansen SG, Powers CJ, Richards R et al (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102–6. doi:10.1126/science.1185350
101. Corrales-Aguilar E, Trilling M, Reinhard H et al (2013) A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. J Immunol Methods 387:21–35. doi:10.1016/j.jim.2012.09.006
102. Linde GA, Hammarström L, Persson MA et al (1983) Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun 42:237–44
103. Gupta CK, Leszczynski J, Gupta RK, Siber GR (1996) IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. Biologicals 24:117–24. doi:10.1006/biol.1996.0015
104. Lubinski JM, Lazear HM, Awasthi S et al (2011) The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J Virol 85:3239–49
105. Ryckman BJ, Chase MC, Johnson DC (2008) HCMV gH/gL/UL128–131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci U S A 105:14118–23. doi:10.1073/pnas.0804365105
106. Spiller OB, Morgan BP, Tufaro F, Devine DV (1996) Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol 26:1532–8. doi:10.1002/eji.1830260719
107. Hwang I, Zhang T, Scott JM et al (2012) Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int Immunol 24:793–802. doi:10.1093/intimm/dxs080
108. Zhang T, Scott JM, Hwang I, Kim S (2013) Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. J Immunol 190:1402–6. doi:10.4049/jimmunol.1203034
109. Gumá M, Angulo A, Vilches C et al (2004) Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664–71. doi:10.1182/blood-2004–05–2058
110. Gumá M, Budt M, Sáez A et al (2006) Expansion of CD94/NKG2C + NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107:3624–31. doi:10.1182/blood-2005–09–3682
111. Wu Z, Sinzger C, Frascaroli G et al (2013) Human cytomegalovirus-induced NKG2C (hi) CD57 (hi) natural killer cells are effectors dependent on humoral antiviral immunity. J Virol 87:7717–25. doi:10.1128/JVI.01096–13
112. Boeckh M, Bowden RA, Storer B et al (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343–51
113. Hodson EM, Jones CA, Strippoli GFM, et al. (2007) Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane database Syst Rev CD005129. doi: 10.1002/14651858.CD005129.pub2
114. Raanani P, Gafter-Gvili A, Paul M et al (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 27:770–81. doi:10.1200/JCO.2008.16.8450
115. Revello MG, Lazzarotto T, Guerra B et al (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316–26. doi:10.1056/NEJMoa1310214
116. Schoppel K, Kropff B, Schmidt C et al (1997) The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175:533–44
117. Powers C, Früh K (2008) Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 197:109–15. doi:10.1007/s00430–007–0073-y
118. Mocarski ES (2002) Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 10:332–9
119. Babic M, Polic B, Krmpotic A et al (2008) Immune evasion of natural killer cells by viruses. Curr Opin Immunol 20:30–38. doi:10.1016/j.coi.2007.11.002
120. Hengel H, Koszinowski UH (1997) Interference with antigen processing by viruses. Curr Opin Immunol 9:470–6
121. Halenius A, Gerke C, Hengel H (2014) Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver? Cell. Mol, Immunol
122. Manley K, Anderson J, Yang F et al (2011) Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10:197–209
123. Letourneur F, Klausner RD (1992) A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell 69:1143–57